UNI-MB - logo
UMNIK - logo
 
E-resources
Peer reviewed Open access
  • Outcome reliability in non-...
    Connolly, Anne M.; Malkus, Elizabeth C.; Mendell, Jerry R.; Flanigan, Kevin M.; Miller, J. Philip; Schierbecker, Jeanine R.; Siener, Catherine A.; Golumbek, Paul T.; Zaidman, Craig M.; Mcdonald, Craig M.; Johnson, Linda; Nicorici, Alina; Karachunski, Peter I.; Day, John W.; Kelecic, Jason M.; Lowes, Linda P.; Alfano, Lindsay N.; Darras, Basil T.; Kang, Peter B.; Quigley, Janet; Pasternak, Amy E.; Florence, Julaine M.

    Muscle & nerve, April 2015, Volume: 51, Issue: 4
    Journal Article

    ABSTRACT Introduction: Therapeutic trials in Duchenne muscular dystrophy (DMD) often exclude non‐ambulatory individuals. Here we establish optimal and reliable assessments in a multicenter trial. Methods: Non‐ambulatory boys/men with DMD (N = 91; 16.7 ± 4.5 years of age) were assessed by trained clinical evaluators. Feasibility (percentage completing task) and reliability intraclass correlation coefficients (ICCs) between morning and afternoon tests were measured. Results: Forced vital capacity (FVC), assessed in all subjects, showed a mean of 47.8 ± 22% predicted (ICC 0.98). Brooke Upper Extremity Functional Rating (Brooke) and Egen Klassifikation (EK) scales in 100% of subjects showed ICCs ranging from 0.93 to 0.99. Manual muscle testing, range of motion, 9‐hole peg test, and Jebsen‐Taylor Hand Function Test (JHFT) demonstrated varied feasibility (99% to 70%), with ICCs ranging from 0.99 to 0.64. We found beneficial effects of different forms of corticosteroids for the Brooke scale, percent predicted FVC, and hand and finger strength. Conclusions: Reliable assessment of non‐ambulatory boys/men with DMD is possible. Clinical trials will have to consider corticosteroid use. Muscle Nerve 51: 522–532, 2015